Pneumonia vaccine study aims to sharpen lab tests

NCT ID NCT07205289

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: GPN Vaccines Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study will give 12 healthy adults a killed whole-cell pneumococcal vaccine called Gamma-PN. The main goal is to collect blood samples to help develop and validate lab tests that measure immune responses. The study does not aim to prove the vaccine works in people, but rather to improve tools for future vaccine research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gamma-PN (killed whole-cell pneumococcal vaccine)
What this could lead to: If successful, this study will help create better lab tests to measure immune responses to pneumococcal vaccines, supporting future vaccine development.
What could go wrong: This is a very early Phase 1 study with only 12 participants, focused on lab test development rather than proving the vaccine works. Results may not translate to larger populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PNEUMOCOCCAL DISEASE PNEUMOCOCCAL DISEASE, INVASIVE

Contacts and locations

Locations

University of Adelaide Clinical Research Facility
RECRUITING

Adelaide, South Australia, 5000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.